Cynata Therapeutics see their organ rejection study published

Company News

by Rachael Jones

Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical model of organ transplant rejection.

The report will be published in Stem Cell Research & Therapy.

Cymerus also limits injury to the transplanted organ.

The treatment led to an i ncrease in human TSG-6, an anti-inflammatory protein, followed by an increase in peripheral mouse regulatory T cells, which play an important role in limiting transplant rejection by establishing immune tolerance.

Shares in Cynata Therapeutics (ASX:CYP) closed -0.93 per cent lower at $1.60 yesterday.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.